Results 151 to 160 of about 281,052 (341)
Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines
Advanced Science, EarlyView.This review offers a comprehensive overview of pharmaceutical nanotechnology strategies to address limitations associated with the complex material basis and relative mild therapeutic efficacy of Chinese herbal medicines, and summarizes the advantages of these strategies.
Jiameng Li +11 more
wiley +1 more source
A phase II trial of paclitaxel in refractory germ cell tumors [PDF]
, 1998 Alan B. Sandler +6 more
openalex +1 more source
Advanced Science, EarlyView.High QSOX2 enhances stemness, drug resistance, and metastasis of ESCC cells. QSOX2‐mediated disulfide bond modification activates mTOR/c‐Myc signaling. CAFs‐secreted IGF‐1 drives mTOR/c‐Myc/QSOX2 positive feedback loop. Combining Ebselen, rapamycin, and cisplatin induces tumor dormancy in mice.
Wo‐Ming Chen +12 more
wiley +1 more source
The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute [PDF]
, 1996 Ross C. Donehower
openalex +3 more sources
The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. [PDF]
, 1996 Yona Kalechman +6 more
openalex +1 more source
History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Ganesh H Divekar +2 more
openaire +2 more sources
Peptide‐Based Biomaterials as a Promising Tool for Cancer Radiotherapy
Advanced Science, EarlyView.This review provides a systematic overview of peptide‐based biomaterials in tumor radiotherapy, covering their roles as both radiosensitizers and radiopharmaceuticals. Peptide‐based radiosensitizers are generally divided into three categories: peptides as direct radiosensitizers, peptides as carriers of radiosensitizers, and targeted‐peptide‐modified ...
Qian Wang, Xinhui Chu, Jianfeng Liu
wiley +1 more source
Paclitaxel in Doxorubicin-Resistant Metastatic Breast Cancer Patients [PDF]
, 1995 Anjali Anand, Anjali Anand
openalex +1 more source
Advanced Science, EarlyView.Novel ATR/PARP1 dual inhibitors are developed for the first time. Advanced lead B8 effectively reduces cell viability in vitro and suppresses tumor growth in vivo, with better potency than ATRi and PARPi alone or in combination. Mechanistically, B8 induces apoptosis, arrests the cell cycle, and inhibits cancer cells colony formation, migration, and ...
Yuan Gao +13 more
wiley +1 more source
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [PDF]
, 2019 Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast ...
Chien, A Jo +5 more
core